EPAS1 and renal cell carcinoma: In this context, the AR has been identified as a potential co-regulator of the HIF2a/VEGF signalling pathway.78 Its activation induces HIF2α/VEGF expression in RCC tumour tissue, subsequently promoting RCC progression.